EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Advancing Leukemia Management Through Liquid Biopsy: Insights into Biomarkers and Clinical Utility

Cíntia Nogueira Hollanda, Ana Cristina Moura Gualberto, Andréa Barretto Motoyama iD, Fabio Pittella-Silva iD

Cancers · 25.04.2025 · 17 (9) · 1438

DOI: 10.3390/cancers17091438 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 25.04.2025. Verfasst von Cíntia Nogueira Hollanda und 3 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Molecular Pathology of Cancer, Faculty of Health Sciences, University of Brasilia, Brasilia 70910-900, Brazil. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 121 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universidade de Brasília, Fundacão de Amparo à Pesquisa do Distrito Federal (FAPDF), Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Liquid biopsy is classically defined as the detection of biomarkers in bodily fluids. One of these biomarkers can be circulating cell-free DNA (cfDNA) released by healthy or cancer cells during apoptosis. These fragments can be quantified and molecularly characterized by techniques like digital droplet PCR (ddPCR) or next-generation sequencing (NGS). By identifying common genetic and epigenetic alterations associated with specific cancer types, cfDNA or circulating tumor DNA (ctDNA) can serve as robust biomarkers for monitoring tumor initiation and progression. Other biomarkers, such as circulating microRNAs (miRNAs), extracellular vesicles, or circulating tumor cells (CTCs) are also applied in this context. Liquid biopsy has gained attention as a versatile tool for cancer diagnostics, prognosis, therapeutic monitoring, and minimal residual disease (MRD) detection across various malignancies, including hematological cancers like myeloid and lymphoid leukemias. Herein, we present a comprehensive review of liquid biopsy usage in leukemia, with a specific focus on the clinical utility of ctDNA, miRNAs, and exosomes in monitoring treatment response, tracking clonal evolution, and detecting minimal residual disease. Our review emphasizes the translational implications of these tools for improving patient outcomes and outlines current challenges in their integration into clinical practice.

Schlagwörter

Stichwörter der Autor:innen

acute lymphoid leukemiaacute myeloid leukemiabiomarkerschronic lymphoid leukemiachronic myeloid leukemialiquid biopsyminimal residual disease (MRD)treatment response

Autor:innen und Institutionen

  • Laboratory of Molecular Pathology of Cancer, Faculty of Health Sciences, University of Brasilia, Brasilia 70910-900, Brazil.

ORCID-Profile: Andréa Barretto Motoyama, Fabio Pittella-Silva

Förderung

  • Universidade de Brasília, Fundacão de Amparo à Pesquisa do Distrito Federal (FAPDF)
  • Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)

Zitieren

APA

Hollanda, C. N., Gualberto, A. C. M., Motoyama, A. B., & Pittella-Silva, F. (2025). Advancing Leukemia Management Through Liquid Biopsy: Insights into Biomarkers and Clinical Utility. Cancers, 17(9), 1438. https://doi.org/10.3390/cancers17091438

Vancouver

Hollanda CN, Gualberto ACM, Motoyama AB, Pittella-Silva F. Advancing Leukemia Management Through Liquid Biopsy: Insights into Biomarkers and Clinical Utility. Cancers. 2025;17(9):1438. doi:10.3390/cancers17091438

BibTeX
@article{Hollanda2025,
  author = {Hollanda, Cíntia Nogueira and Gualberto, Ana Cristina Moura and Motoyama, Andréa Barretto and Pittella-Silva, Fabio},
  title = {Advancing Leukemia Management Through Liquid Biopsy: Insights into Biomarkers and Clinical Utility},
  journal = {Cancers},
  year = {2025},
  volume = {17},
  number = {9},
  pages = {1438},
  doi = {10.3390/cancers17091438}
}
Kostenlos starten →